These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

890 related items for PubMed ID: 16731298

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG, Fischer ER, Harris DC.
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U, PROTOS Study Investigators.
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [Abstract] [Full Text] [Related]

  • 8. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J, Rivera MT, Torrente J, Portolés J, Gomez-Martino JR.
    J Nephrol; 2003 Jul; 16(5):697-702. PubMed ID: 14733416
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
    Piccoli A, Malagoli A, Komninos G, Pastori G.
    J Nephrol; 2002 Jul; 15(5):565-74. PubMed ID: 12455725
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [Abstract] [Full Text] [Related]

  • 12. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, Kim HJ, Noh JW.
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [Abstract] [Full Text] [Related]

  • 13. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U, RUBRA Study Investigators.
    Am J Nephrol; 2008 Oct; 28(2):280-9. PubMed ID: 18004064
    [Abstract] [Full Text] [Related]

  • 14. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C, Frei D, Perkins AC.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [Abstract] [Full Text] [Related]

  • 15. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population.
    Vercaigne LM, Collins DM, Penner SB.
    J Clin Pharmacol; 2005 Aug; 45(8):895-900. PubMed ID: 16027399
    [Abstract] [Full Text] [Related]

  • 16. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H, Wang SX.
    Blood Purif; 2008 Aug; 26(2):151-6. PubMed ID: 18212498
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A, Epoetin Zeta Study Group.
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [Abstract] [Full Text] [Related]

  • 18. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM, Muirhead N, Wazny LD, Gallo KL, Heidenheim AP, House AA.
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [Abstract] [Full Text] [Related]

  • 19. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase.
    Galliford JW, Malasana R, Farrington K.
    Nephrol Dial Transplant; 2005 Sep; 20(9):1956-62. PubMed ID: 15930017
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
    Haag-Weber M, Vetter A, Thyroff-Friesinger U, INJ-Study Group.
    Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.